SCHEMBL16369613

SCHEMBL16369613

CC(C)C(C(=O)Nc1ncc(F)s1)c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 20/20 1.00
▸ MEN1 O00255 1/20 0.62
▸ LMNA P02545 1/20 0.62
▸ KMT2A Q03164 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16369612 1.00 FFAR2 (1.00) FFAR2MEN1LMNAKMT2A
SCHEMBL2021216 0.83 FFAR2 (0.80) FFAR2MEN1LMNAKMT2A
SCHEMBL27713666 0.81 FFAR2 (0.71) FFAR2MEN1LMNAKMT2A
SCHEMBL16369644 0.77 FFAR2 (1.00) FFAR2MEN1LMNAKMT2A
SCHEMBL16369642 0.77 FFAR2 (1.00) FFAR2MEN1LMNAKMT2A
SCHEMBL2753331 0.76 MEN1 (0.72) FFAR2MEN1LMNAKMT2A
SCHEMBL11309036 0.73 FFAR2 (0.80) FFAR2MEN1LMNAKMT2A
SCHEMBL2017590 0.72 FFAR2 (0.64) FFAR2MEN1LMNAKMT2A
SCHEMBL2659368 0.71 GCK (0.64) FFAR2
SCHEMBL20788538 0.71 FFAR2 (1.00) FFAR2MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130989-A9 ALLERGY TREATMENT PROTA THERAPEUTICS PTY LTD (AU) 2026-05-14 — — US disclosed
US-20250381267-A1 ALLERGY TREATMENT PROTA THERAPEUTICS PTY LTD (AU) 2025-12-18 — — US disclosed
US-20230049005-A1 ALLERGY TREATMENT PROTA THERAPEUTICS PTY LTD (AU) 2023-02-16 — — US disclosed
WO-2021127736-A1 ALLERGY TREATMENT PROTA THERAPEUTICS PTY LTD (AU) 2021-07-01 — — WO disclosed
US-20190134179-A1 COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE VEDANTA BIOSCIENCES, INC. (US) 2019-05-09 — — US disclosed
US-10130695-B2 Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease VEDANTA BIOSCIENCES, INC. (US) 2018-11-20 — — US disclosed
US-20180000921-A1 COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE VEDANTA BIOSCIENCES, INC. (US) 2018-01-04 — — US disclosed
US-9764019-B2 Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease VEDANTA BIOSCIENCES, INC. (US) 2017-09-19 — — US disclosed
US-20160144014-A1 COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE VEDANTA BIOSCIENCES (US) 2016-05-26 — — US disclosed
EP-3019181-A2 COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE Puretech Ventures, LLC (US) 2016-05-18 — — EP disclosed
WO-2015006355-A2 COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE PURETECH VENTURES, LLC (US) 2015-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260130989-A9 ALLERGY TREATMENT FCER2, HRH2, FCGR3B FFAR2 854/4885MEN1 4543/4885LMNA 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback